A phase II safety and efficacy study of PM8002 (anti-PD-L1 x VEGF-A bispecific) combined with paclitaxel as a second-line therapy for small cell lung cancer (SCLC)

被引：1
|
作者：
Cheng, Y. [1 ]
Qin, Z. [2 ]
Meng, X. [3 ]
Xu, F. [4 ]
Wang, Y. [5 ]
Yao, Y. [6 ]
Fang, J. [7 ]
Zhao, Y. [8 ]
机构：
[1] Jilin Canc Hosp, Med Oncol, Changchun, Peoples R China
[2] Zhejiang Prov Peoples Hosp, Med Oncol, Hangzhou, Peoples R China
[3] Shandong Canc Hosp, Radiat Oncol, Jinan, Peoples R China
[4] Nanchang Univ, Resp Med, Affiliated Hosp 1, Nanchang, Jiangxi, Peoples R China
[5] Harbin Med Univ, Resp Med, Canc Hosp, Harbin, Heilongjiang, Peoples R China
[6] Xi An Jiao Tong Univ, Med Oncol, Affiliated Hosp 1, Xian, Peoples R China
[7] Peking Univ, Thorac Med Oncol, Canc Hosp, Beijing, Peoples R China
[8] Henan Canc Hosp, Resp Med, Zhengzhou, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.1223
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1992P
引用
收藏
页码：S1062 / S1062
页数：1
相关论文
共 50 条
  • [31] Efficacy and safety of PD-1/PD-L1 inhibitors plus nab-paclitaxel with or without bevacizumab as second-line therapy or beyond for patients with metastatic non-small-cell lung cancer.
    Zhang, Fan
    Li, Tao
    Zhang, Yuzi
    Cai, Shangli
    Zhao, Lei
    Jiao, Shun Chang
    Hu, Yi
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [32] A Network Meta-analysis Comparing the Efficacy and Safety of Anti-PD-1 with Anti-PD-L1 in Non-small Cell Lung Cancer
    You, Wei
    Liu, Mei
    Miao, Ji-Dong
    Liao, Yu-Qian
    Song, Yi-Bing
    Cai, Dian-Kun
    Gao, Yang
    Peng, Hao
    JOURNAL OF CANCER, 2018, 9 (07): : 1200 - 1206
  • [33] Efficacy and safety analysis of anlotinib combined with immunotherapy as second-line therapy for advanced non-small cell lung cancer (NSCLC)
    Shi, Q.
    Xie, Q.
    Lin, H.
    He, Y.
    Zheng, X.
    Zhou, Z.
    ANNALS OF ONCOLOGY, 2022, 33 : S1568 - S1568
  • [34] ZD0473 as second-line therapy in non-small cell lung cancer: A Phase II study
    Treat, J
    Huang, C
    Damanjov, N
    Jahenzeb, M
    Edelman, M
    Koehler, M
    LUNG CANCER: CURRENT TOPICS, 2001, : 341 - 344
  • [35] A multi-center phase II study of weekly topotecan as second-line therapy for small cell lung cancer
    Shah, Chirag
    Ready, Neal
    Perry, Michel
    Kirshner, Jeffrey
    Gajra, Ajeet
    Neuman, Nancy
    Garziano, Stephen
    LUNG CANCER, 2007, 57 (01) : 84 - 88
  • [36] Phase II study of fenretinide in patients with small cell lung cancer (SCLC) with progression after first- or second-line chemotherapy.
    Schneider, BJ
    Worden, F
    Gadgeel, S
    Hodges, C
    Parchment, R
    Zwiebel, J
    Kraut, M
    Kalemkerian, G
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 690S - 690S
  • [37] Phase II study of oral topotecan plus bevacizumab (topo-bev) for second-line treatment of small cell lung cancer (SCLC)
    Waterhouse, D. M.
    Morgan, S. K.
    Spigel, D. R.
    Shankar, S.
    Dharan, B.
    Foose, D. E.
    Bhatt, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [38] Phase II study of doxorubicin and paclitaxel as second-line chemotherapy of small-cell lung cancer - A Hoosier Oncology Group Trial
    Sonpavde, G
    Ansari, R
    Walker, P
    Sciortino, DF
    Gabrys, GT
    Murdock, A
    Gonin, R
    Einhorn, LH
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2000, 23 (01): : 68 - 70
  • [39] Efficacy and safety of anti-PD-1 inhibitor versus anti-PD-L1 inhibitor in first-line treatment of extensive-stage small cell lung cancer: a multicenter retrospective study
    Boyu Qin
    Lingli Xin
    Chen Liang
    Lingling Li
    Qi Song
    Yaping Long
    Xiaoling Zhang
    Dan Wang
    Weiwei Shi
    Jing Zhang
    Yi Hu
    Bo Yang
    Qi Xiong
    BMC Cancer, 24
  • [40] Efficacy and safety of anti-PD-1 inhibitor versus anti-PD-L1 inhibitor in first-line treatment of extensive-stage small cell lung cancer: a multicenter retrospective study
    Qin, Boyu
    Xin, Lingli
    Liang, Chen
    Li, Lingling
    Song, Qi
    Long, Yaping
    Zhang, Xiaoling
    Wang, Dan
    Shi, Weiwei
    Zhang, Jing
    Hu, Yi
    Yang, Bo
    Xiong, Qi
    BMC CANCER, 2024, 24 (01)
12345